<DOC>
	<DOCNO>NCT01511692</DOCNO>
	<brief_summary>This trial conduct Europe Oceania . The aim trial ass effect liraglutide energy intake subject type 2 diabetes .</brief_summary>
	<brief_title>Effect Liraglutide Compared Glimepiride Appetite Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes mellitus Diettreated subject and/or subject type 2 diabetes OAD ( oral antidiabetic drug ) monotherapy HbA1c diettreated subject : HbA1c 6.510.0 % ( inclusive ) OAD treat subject : HbA1c 6.59.5 % ( inclusive ) Body mass index ( BMI ) 2740 kg/m^2 ( inclusive ) Subjects stable body weight least 3 month prior screen ( document weight within 3 6 month , prior screen within 15 % screen weight ) Euthyroid subject Subjects unrestrained eater Recurrent severe hypoglycaemia Impaired liver function Impaired renal function Cardiac problem Uncontrolled treated/untreated hypertension Known suspect allergy trial product relate product Use drug ( except OADs ) , investigator 's opinion could interfere subject 's glucose level body weight Active hepatitis B and/or active hepatitis C Positive HIV ( human immunodeficiency virus ) antibodies Known suspect abuse alcohol narcotic Habitual excessive consumption methylxanthinecontaining beverage food ( coffee , tea , cola drink , chocolate ) judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>